论文部分内容阅读
目的观察门冬氨酸钾镁在治疗慢性心力衰竭合并低钾、低镁血症患者的临床疗效。方法将患者随机分成A、B两组,A组静滴5%葡萄糖注射液+门冬氨酸钾镁液;B组静滴5%葡萄糖注射液+氯化钾注射液+硫酸镁注射液。剂量均根据每天监测的血钾、血镁、血钠浓度来决定。结果 A组(42例):血钾氯镁正常40例(95.2%);低钾、低镁血症1例(2.4%);无高钾、高镁血症和高氯血症;低氯血症1例(2.4%)。B组(38例):血钾、氯、镁正常31例(81.5%);低钾、低镁血症2例(5.3%);无高钾、高镁血症;高氯血症2例(5.3%);低氯血症3例(7.9%)。A组经治疗后电解质正常比例明显高于B组,其P值<0.05,有统计学意义。结论门冬氨酸钾镁在治疗慢性心力衰竭合并低钾、低镁血症的患者,疗效肯定,且出现高钾、高镁或高氯血症的情况少,安全性好,值得推广运用,尤其是在基层医院。
Objective To observe the clinical efficacy of potassium and magnesium aspartate in the treatment of patients with chronic heart failure complicated with hypokalemia and hypomagnesemia. Methods Patients were randomly divided into A, B two groups, A group of intravenous infusion of 5% glucose and magnesium aspartate solution; B group infusion of 5% glucose injection + potassium chloride injection + magnesium sulfate injection. The dose is based on the daily monitoring of serum potassium, serum magnesium, serum sodium concentration to decide. Results Group A (n = 42) had 40 cases (95.2%) with normal serum potassium and magnesium, 1 case (2.4%) with hypokalemia and hypomagnesemia, no hyperkalemia, hypermagnesemia and hyperchloremia, 1 case of hyperlipidemia (2.4%). Group B (n = 38) had 31 cases (81.5%) of normal serum potassium, chloride and magnesium, 2 cases (5.3%) of hypokalemia and hypomagnesemia, 2 cases of high potassium and hypermagnesemia (5.3%); hypochlorosis in 3 cases (7.9%). A group after treatment, the normal electrolyte ratio was significantly higher than the B group, the P value <0.05, statistically significant. Conclusion Potassium and magnesium aspartate in the treatment of patients with chronic heart failure combined with hypokalemia and hypomagnesemia have definite curative effect and few cases of high potassium, high magnesium or chloramphenicol. They are safe and worthy of promotion. Especially in primary hospitals.